TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Nutriband CEO Publishes Letter to Shareholders

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Gareth Sheridan, Ceo
Nutriband CEO Publishes Letter to Shareholders

Nutriband Inc. reported significant progress in 2025 including the sale of 90% of its Pocono subsidiary to EarthVision Bio for $5M with no shareholder dilution, a 25% preferred stock dividend, and major advances in its lead product AVERSA Fentanyl abuse-deterrent patch. The company received FDA Type C Meeting approval, completed manufacturing scale-up, secured additional patents, and was added to four Russell indexes. The CEO highlighted shareholder value focus and anticipated warrant expiration in October 2026 as a potential positive catalyst.

Insights
BMLpL   neutral

The announcement indicates a strategic increase in financial instruments without explicit positive or negative implications, representing a neutral market movement


NTRB   positive

Company demonstrated strong progress toward commercialization of lead product AVERSA Fentanyl with FDA Type C Meeting approval, patent issuances, manufacturing scale-up completion, and strategic capital management through subsidiary sale without shareholder dilution. Addition to Russell indexes and preferred stock dividend also indicate positive momentum.